Reference

Perindopril, converting enzyme blockade, and peripheral arterial hemodynamics in the healthy volunteer

Perindopril, converting enzyme blockade, and peripheral arterial hemodynamics in the healthy volunteer. Richer, C.; Thuillez, C.; Giudicelli, J. F. (Serv. Pharmacol. Clin., Hop. Bicetre, Le Kremlin-Bicetre 94275, Fr.). J. 52-39-1 and 9015-82-1 which are cas registry numbers are also used here. Cardiovasc. Pharmacol., 9(1), 94-102 (English) 1987. CODEN: JCPCDT. ISSN: 0160-2446. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) The effects of three doses (4, 8, and 16 mg) of perindopril tert-butylamine salt (I) [107133-36-8], a new angiotensin I converting enzyme [9015-82-1] inhibitor, on systemic blood pressure, heart rate, brachial and carotid artery flow and diam. (assessed by the pulsed Doppler technique), forearm vascular resistance, plasma converting enzyme and renin [9015-94-5] activities, and plasma aldosterone [52-39-1] were investigated in the normal volunteer and compared with those of a placebo over a 24-h period following oral drug intake in a double-blind, cross-over trial. I dose-dependently decreased plasma converting enzyme activity, an effect that peaked at 3-4 h and persisted up to at least 48 h. Plasma renin activity increased for 12 h and plasma aldosterone was slightly decreased. Systemic blood pressure and heart rate were not drug-affected but I dose-dependently augmented brachial and carotid artery flow, indicating an increase in peripheral arterial compliance. These vasodilating effects, which lasted up to 10 h after drug intake, affected both large arteries and arterioles, the latter being more sensitive, however, and were more marked in the muscular resistance vessels. .

Process for industrially-viable preparation of perindopril erbumine

All Rights Reserved. Process for industrially-viable preparation of perindopril erbumine. 82834-12-6 and 107133-36-8 are also occured in this study. Potluri, Ramesh Babu; Venkata Subramanian, Hariharakrishnan; Mulakala, Atchuta Ramayya Chowdary; Kodali, Hari Prasad (India ). PCT Int. Appl. WO 2006137082 A1 28 Dec 2006,17pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. APPLICATION: WO 2006-IN182 29 May 2006. PRIORITY: IN 2005-CH783 23 Jun 2005. DOCUMENT TYPE: Patent CA Section: 34 (Amino Acids, Peptides, and Proteins) A novel method for the prepn. of perindopril erbumine [(2S,3aS,7aS)-1-[N-[(S)-1-(ethoxycarbonyl)butyl]-L-alanyl]octahydro-1H- indole-2-carboxylic acid tert-butylamine salt] comprises treating (2S,3aS,7aS)-octahydro-1H-indole-2-carboxylic acid (I) esters with N-[(S)-1-(ethoxycarbonyl)butyl]-L-alanine, followed by deprotection and conversion to the erbumine salt. I benzyl ester hydrochloride was prepd. from hexahydroindoline-2-carboxylic acid hydrochloride by catalytic hydrogenation, followed by esterification and resoln. with dibenzoyl-L-tartaric acid or benzyloxycarbonyl-L-phenylalanine. .